Alpha 2.0
Login Register
» Articles » PMID: 38390211

Glycemic Control in Children with Type 1 Diabetes Treated with the Advanced Hybrid Closed Loop System 2-year Prospective, Observational, Two-center Study

Overview
Journal Front Endocrinol (Lausanne)
Specialty Endocrinology
Date 2024 Feb 23
PMID 38390211
Authors
Sebastian Seget
Agata Chobot
Mateusz Tarasiewicz
Anna Bielawska
Ewa Rusak
Agnieszka Ochab
Joanna Polanska
Przemyslawa Jarosz-Chobot
Affiliations
Soon will be listed here.
Abstract

Background And Aims: MiniMed 780G is the first Advanced Hybrid Closed Loop (AHCL) system in Poland, approved in the EU in 2020. To date, observations of glycemic control up to 12 months have been published. This study aimed to analyze glycemic control and anthropometric parameters in children and adolescents with type 1 diabetes (T1D) after two years of using the AHCL system.

Materials And Methods: We prospectively collected anthropometric data, pump, and continuous glucose records of fifty T1D children (9.9 ± 2.4 years, 24 (48%) boys, T1D for 3.9 ± 2.56 years) using an AHCL system. We compared the two-week AHCL records obtained after AHCL enrollment with data 6, 12, and 24 months after starting AHCL.

Results: Time in range (70-180 mg/dl) and BMI z-score did not change during the 2 years of observation (p>0.05). The percentage of autocorrection in total daily insulin increased significantly (p<0.005).

Conclusion: Glycemic control in the investigated group of children with T1D treated with the AHCL system for 2 years remained stable. Children in this group maintained weight and optimal metabolic control, most likely due to autocorrection boluses.

Citing Articles

Long-term use of Minimed™ 780G in children and adolescents with type 1 diabetes under real-world conditions: The benefits of optimal settings.

Bombaci B, Passanisi S, Calderone M, Macri F, Lombardo F, Salzano G Diabetes Obes Metab. 2025; 27(4):2309-2312.

PMID: 39887516 PMC: 11885100. DOI: 10.1111/dom.16226.

Real world efficacy and safety of the advanced hybrid closed-loop system MiniMed 780G (SmartGuard) in children under 7 years of age.

Lopez-Lopez S, Diaz-Martin C, Garcia-de Pablo I, Ovejero-Garcia M, Garnier-Rodriguez M, Molina-Suarez R Front Med (Lausanne). 2025; 11():1465800.

PMID: 39835094 PMC: 11743179. DOI: 10.3389/fmed.2024.1465800.

Children and adolescent with suboptimal control of type 1 diabetes improve during the first 2 years on automated insulin delivery system.

Kiilavuori M, Varimo T, Tuomaala A, Pulkkinen M Diabetes Obes Metab. 2024; 27(1):134-142.

PMID: 39344828 PMC: 11618217. DOI: 10.1111/dom.15992.

Impact of School Nurse on Managing Pediatric Type 1 Diabetes with Technological Devices Support: A Systematic Review.

Cangelosi G, Mancin S, Morales Palomares S, Pantanetti P, Quinzi E, Debernardi G Diseases. 2024; 12(8).

PMID: 39195172 PMC: 11353902. DOI: 10.3390/diseases12080173.

Investigating the Incidence of Dyslipidemia among Brazilian Children and Adolescents Diagnosed with Type 1 Diabetes Mellitus: A Cross-Sectional Study.

Fagundes Melo R, Fornari Laurindo L, Sloan K, Sloan L, Cressoni Araujo A, Bitelli P Diseases. 2024; 12(3).

PMID: 38534969 PMC: 10968983. DOI: 10.3390/diseases12030045.

References
1.
Pulkkinen M, Varimo T, Hakonen E, Harsunen M, Hyvonen M, Janer J . MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks. Diabetes Technol Ther. 2022; 25(2):100-107. DOI: 10.1089/dia.2022.0313. View
2.
Seget S, Rusak E, Polanska J, Jarosz-Chobot P . Prospective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 Diabetes. Diabetes Technol Ther. 2022; 24(11):824-831. PMC: 9618370. DOI: 10.1089/dia.2022.0148. View
3.
Tornese G, Carletti C, Giangreco M, Nistico D, Faleschini E, Barbi E . Carbohydrate Tolerance Threshold for Unannounced Snacks in Children and Adolescents With Type 1 Diabetes Using an Advanced Hybrid Closed-Loop System. Diabetes Care. 2022; 45(6):1486-1488. PMC: 9210515. DOI: 10.2337/dc21-2643. View
4.
Rachmiel M, Lebenthal Y, Mazor-Aronovitch K, Brener A, Levek N, Jacobi-Polishook T . MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience. Diabetes Technol Ther. 2023; 25(9):643-651. DOI: 10.1089/dia.2023.0081. View
5.
Shalit R, Minsky N, Laron-Hirsh M, Cohen O, Kurtz N, Roy A . Unannounced Meal Challenges Using an Advanced Hybrid Closed-Loop System. Diabetes Technol Ther. 2023; 25(9):579-588. DOI: 10.1089/dia.2023.0139. View